世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アレルギー診断薬と治療薬の市場規模、シェア、動向分析レポート:タイプ別(診断薬、治療薬)、アレルゲンタイプ別(食品、吸入、薬剤)、検査タイプ別、地域別、セグメント別予測、2024年~2030年


Allergy Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Allergen Type (Food, Inhaled, Drug), By Test Type, By Region, And Segment Forecasts, 2024 - 2030

アレルギー診断と治療薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界のアレルギー診断・治療薬市場規模は2023年に583億1000万米ドルと推定され、2024年から2030年にかけて年平均... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月11日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報・注文方法はこちら
150 英語

1~3営業日


 

サマリー

アレルギー診断と治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のアレルギー診断・治療薬市場規模は2023年に583億1000万米ドルと推定され、2024年から2030年にかけて年平均成長率(CAGR)8.7%で成長すると予測されている。アレルギー疾患の罹患率の増加は、先進的な治療薬への需要と相まって、今後数年間の市場成長を促進すると予測されている。米国アレルギー喘息免疫学会(AAAAI)が発表した推計によると、アレルギー性鼻炎は世界人口の約10〜30%が罹患しており、世界的にアレルギー治療薬の採用に影響を与えている。

治療成績の向上や疾病管理のための人工知能技術の使用など、技術的に高度な製品の統合が進んでいることは、開業医の意思決定プロセスに役立っている。さらに、鼻炎などのアレルギーを診断するためのmHealthアプリの採用が増加していることも、市場を押し上げると予想される。例えば、MASK-Airアプリはアレルギー性鼻炎に特化している。

モノクローナル抗体は、その高い有効性、長期にわたる忍容性、安全性により、特定のアレルギーの懸念を払拭する新しい治療法の開発に貢献すると予想される。そのため、主要企業は、特にモノクローナル抗体のような選択的な標的を対象とした、標的特異的なメカニズムで設計された新規かつ効果的な生物学的製剤を開発している。さらに、アレルギー疾患に対する非常に重要なモノクローナル抗体の一貫した製品承認は、成長の範囲を拡大すると予想される。

抗免疫グロブリンE(IgE)抗体、サイトカインモジュレーター、DNAワクチン接種などの新しい治療法がアレルギー疾患の治療に用いられている。オマリズマブは組換えヒト化IgG1モノクローナル抗IgE抗体で、アレルギー性の慢性蕁麻疹や喘息の治療に使用される。2021年4月、ジェネンテック(ロシュ・グループ)は、自己注射用プレフィルドシリンジが、慢性特発性蕁麻疹アレルギー性喘息および鼻ポリープを適応症とするゾレア(オマリズマブ)のFDA承認を米国で取得したと発表した。

アレルギー診断薬・治療薬市場は、Merck & Co., Inc.、Thermo Fisher Scientific, Inc.、Abbott、Pfizer, Inc.これらの企業は、能力を高め、製品ポートフォリオを拡大し、能力を向上させるために様々な取り組みを行っている。

アレルギー診断と治療薬市場レポートハイライト

- 消耗品製品セグメントは、2022年のアレルギー診断薬・治療薬市場で最大のシェアを占めた。感度、精度、検出速度の向上につながるMeDALLアレルゲンチップを含む製品の登場が市場成長を促進すると予測される

- 薬物アレルギー分野は、治療選択肢の増加や患者の薬物アレルギーに対する意識の高まりにより、高成長が期待される。

- 喘息、鼻炎、アレルギー性結膜炎などのアレルギー発症率の増加、世界的なアレルギー検査需要の高まりにより、2022年は試験管内検査が最も高いシェアを占める

- エピネフリンが2022年の薬物クラス別セグメントを支配。主要企業による費用対効果の高いエピネフリン自己注射器の導入は、市場成長を大幅に増大させると予想される

- 2022年のアレルギー診断薬・治療薬市場は、アレルギー治療薬に関連する高い可能性に対する理解の高まりにより、北米が支配的となった。このため、米国を拠点とする企業は、これらの医薬品の開発にかなりの投資を行うようになった。

- アジア太平洋地域は、特に喘息、慢性咳嗽、食物アレルギーの罹患率が上昇していることから、今後かなりの成長が見込まれる。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.5.1. Commodity Flow Analysis
1.5.1.1. Approach 1: Commodity flow approach
1.5.1.2. Approach 2: Country-wise market estimation using bottom-up approach
1.6. Data Validation & Publishing
1.7. Global Market: CAGR Calculation
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segmental Snapshot
2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. Allergy Diagnostics & Therapeutics Market - Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising incidence of allergies
3.2.1.2. Advancements in technology and launch of new products
3.2.1.3. High adoption of immunotherapy drugs
3.2.2. Market Restraint Analysis
3.2.2.1. Low adoption and penetration in developing countries due to the high cost of technology
3.2.2.2. Lack of allergen standardization
3.3. Business Environmental Tools Analysis: Allergy Diagnostics & Therapeutics Market
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.4. Pipeline Analysis
Chapter 4. Allergy Diagnostics & Therapeutics Market: Type Estimates & Trend Analysis
4.1. Allergy Diagnostics & Therapeutics Market, By Type: Key Takeaways
4.2. Allergy Diagnostics & Therapeutics Market: Type Movement & Market Share Analysis, 2023 & 2030
4.3. Diagnostics
4.3.1. Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.2. Instruments
4.3.2.1. Global Instruments Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.3. Consumables
4.3.3.1. Global Consumables Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.4. Services
4.3.4.1. Global Services Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4. Therapeutics
4.4.1. Global Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2. Antihistamines
4.4.2.1. Global Antihistamines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3. Decongestants
4.4.3.1. Global Decongestants Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.4. Corticosteroids
4.4.4.1. Global Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.5. Mast Cell Stabilizers
4.4.5.1. Global Mast Cell Stabilizers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.6. Leukotriene Inhibitors
4.4.6.1. Global Leukotriene Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.7. Nasal Anti-cholinergic
4.4.7.1. Global Nasal Anti-cholinergic Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.8. Immuno-modulators
4.4.8.1. Global Immuno-modulators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.9. Epinephrine
4.4.9.1. Global Epinephrine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.10. Immunotherapy
4.4.10.1. Global Immunotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Allergy Diagnostics & Therapeutics Market: Allergen Type Estimates & Trend Analysis
5.1. Allergy Diagnostics & Therapeutics Market, By Allergen type: Key Takeaways
5.2. Allergy Diagnostics & Therapeutics Market: Allergen type Movement & Market Share Analysis, 2023 & 2030
5.3. Food
5.3.1. Global Food Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.2. Dairy Products
5.3.2.1. Global Dairy Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.3. Poultry Product
5.3.3.1. Global Poultry Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.4. Tree Nuts
5.3.4.1. Global Tree Nuts Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.5. Peanuts
5.3.5.1. Global Peanut Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.6. Shellfish
5.3.6.1. Global Shellfish Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.7. Wheat
5.3.7.1. Global Wheat Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.8. Soy
5.3.8.1. Global Soy Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.9. Other Food Allergens
5.3.9.1. Global Food Allergens Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4. Inhaled
5.4.1. Global Inhaled Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5. Drug
5.5.1. Global Drug Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6. Others allergen types
5.6.1. Global Other allergen types Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Allergy Diagnostics Market: Test Type Estimates & Trend Analysis
6.1. Allergy Diagnostics Market, By Test Type: Key Takeaways
6.2. Allergy Diagnostics Market: Test Type Movement & Market Share Analysis, 2023 & 2030
6.3. In Vivo tests
6.3.1. Global In Vivo tests Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2. Skin Prick Test
6.3.2.1. Global Skin Prick Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3. Intradermal Test
6.3.3.1. Global Intradermal Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4. Patch Test
6.3.4.1. Global Patch Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4. In Vitro tests
6.4.1. Global In Vitro tests Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Allergy Diagnostics & Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Allergy Diagnostics & Therapeutics Market: Regional Movement Analysis, 2023 & 2030
7.2. North America
7.2.1. North America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Prevalence Insights
7.2.2.4. Regulatory Framework
7.2.2.5. Reimbursement Structure
7.2.2.6. U.S. Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Prevalence Insights
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Structure
7.2.3.6. Canada Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Prevalence Insights
7.3.2.4. Regulatory Framework
7.3.2.5. Reimbursement Structure
7.3.2.6. UK Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Prevalence Insights
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Structure
7.3.3.6. Germany Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Prevalence Insights
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Structure
7.3.4.6. France Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Prevalence Insights
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Structure
7.3.5.6. Italy Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Prevalence Insights
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Structure
7.3.6.6. Spain Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Prevalence Insights
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Structure
7.3.7.6. Denmark Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Prevalence Insights
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Structure
7.3.8.6. Sweden Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Prevalence Insights
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Structure
7.3.9.6. Norway Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Prevalence Insights
7.4.2.4. Regulatory Framework
7.4.2.5. Reimbursement Structure
7.4.2.6. Japan Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Prevalence Insights
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Structure
7.4.3.6. China Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Prevalence Insights
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Structure
7.4.4.6. India Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Prevalence Insights
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Structure
7.4.5.6. Australia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Prevalence Insights
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Structure
7.4.6.6. Thailand Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Prevalence Insights
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Structure
7.4.7.6. South Korea Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Prevalence Insights
7.5.2.4. Regulatory Framework
7.5.2.5. Reimbursement Structure
7.5.2.6. Brazil Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Prevalence Insights
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Structure
7.5.3.6. Mexico Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Prevalence Insights
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Structure
7.5.4.6. Argentina Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East & Africa
7.6.1. Middle East & Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Prevalence Insights
7.6.2.4. Regulatory Framework
7.6.2.5. Reimbursement Structure
7.6.2.6. South Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Prevalence Insights
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Structure
7.6.3.6. Saudi Arabia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Prevalence Insights
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Structure
7.6.4.6. UAE Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Prevalence Insights
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Structure
7.6.5.6. Kuwait Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Company Market Share Analysis, 2023
8.3. Strategy Mapping
8.4. Company Profiles/Listing
8.4.1. R-Biopharm AG
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. EUROIMMUN Medizinische Labordiagnostika AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. DASIT Group SPA
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. AESKU.GROUP GmbH
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. bioMérieux
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Danaher
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Thermo Fisher Scientific, Inc
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Stallergenes Greer
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Minaris Medical America, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Siemens Healthcare GmbH
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Omega Diagnostics Group PLC
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. HYCOR Biomedical
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Lincoln Diagnostics, Inc.
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
8.4.14. Alcon
8.4.14.1. Overview
8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.14.3. Product Benchmarking
8.4.14.4. Strategic Initiatives
8.4.15. HOB Biotech Group Corp., Ltd.
8.4.15.1. Overview
8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.15.3. Product Benchmarking
8.4.15.4. Strategic Initiatives
8.4.16. AbbVie Inc.
8.4.16.1. Overview
8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.16.3. Product Benchmarking
8.4.16.4. Strategic Initiatives
8.4.17. Allergy Therapeutics
8.4.17.1. Overview
8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.17.3. Product Benchmarking
8.4.17.4. Strategic Initiatives
8.4.18. Sanofi
8.4.18.1. Overview
8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.18.3. Product Benchmarking
8.4.18.4. Strategic Initiatives
8.4.19. Pfizer Inc.
8.4.19.1. Overview
8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.19.3. Product Benchmarking
8.4.19.4. Strategic Initiatives
8.4.20. Teva Pharmaceutical Industries Ltd.
8.4.20.1. Overview
8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.20.3. Product Benchmarking
8.4.20.4. Strategic Initiatives
8.4.21. Sun Pharmaceutical Industries Ltd.
8.4.21.1. Overview
8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.21.3. Product Benchmarking
8.4.21.4. Strategic Initiatives
8.4.22. GSK plc
8.4.22.1. Overview
8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.22.3. Product Benchmarking
8.4.22.4. Strategic Initiatives
8.4.23. F. Hoffmann-La Roche Ltd.
8.4.23.1. Overview
8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.23.3. Product Benchmarking
8.4.23.4. Strategic Initiatives
8.4.24. Merck & Co., Inc.
8.4.24.1. Overview
8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.24.3. Product Benchmarking
8.4.24.4. Strategic Initiatives
8.4.25. Astellas Pharma Inc.
8.4.25.1. Overview
8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.25.3. Product Benchmarking
8.4.25.4. Strategic Initiatives

 

ページTOPに戻る


 

Summary

Allergy Diagnostics And Therapuetics Market Growth & Trends

The global allergy diagnostics and therapeutics market size was estimated at USD 58.31 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing incidences of allergic diseases, coupled with demand for advanced therapeutics, is expected to drive the market growth in the coming years. According to estimates published by the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects approximately 10-30% of the global population, thereby impacting the adoption of allergy therapeutics globally.

The increasing integration of technologically advanced products, such as the use of artificial intelligence technology to advance treatment outcomes and manage diseases, helps practitioners in the decision-making process. Furthermore, the rising adoption of mHealth apps for diagnosing allergies such as rhinitis is expected to boost the market. For instance, the MASK-Air app is dedicated specifically to allergic rhinitis.

Monoclonal antibodies are anticipated to contribute to the development of new therapies that eradicate specific allergy concerns, owing to their higher efficacy, long-term tolerability, and safety. Hence, key companies are developing novel & effective biologic-based therapies designed with target-specific mechanisms directed toward selective targets, especially monoclonal antibodies. In addition, consistent product approvals of highly significant monoclonal antibodies for allergy disorders are anticipated to expand the scope for growth.

New therapies such as anti-immunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations are being used to treat allergic disorders. Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, which is used for treating allergic chronic urticaria and asthma. In April 2021, Genentech (Roche Group) announced that its prefilled syringe for self-injection has received FDA approval for Xolair (omalizumab) in the U.S. for chronic idiopathic urticaria allergic asthma, and nasal polyps.

The allergy diagnostics & therapeutics market is moderately competitive, with a strong presence of notable companies such as Merck & Co., Inc, Thermo Fisher Scientific, Inc., Abbott, and Pfizer, Inc. These players are undertaking various initiatives to increase their capabilities, expand their product portfolios, and improve their competencies.

Allergy Diagnostics And Therapuetics Market Report Highlights

• The consumables product segment held the largest share in the allergy diagnostics & therapeutics market in 2022. The advent of products that include the MeDALL allergen-chip, which is linked with increased sensitivity, precision, and faster detection, is anticipated to encourage market growth

• The drug allergies segment is expected to advance lucratively due to the increasing availability of treatment options and growing awareness about drug allergies among patients

• In vitro tests accounted for the highest share in 2022 due to an increase in the incidence of allergies such as asthma, rhinitis, & allergic conjunctivitis, and a rise in demand for allergy testing globally

• Epinephrine dominated the drug class segment in 2022. The introduction of cost-effective epinephrine autoinjectors by key companies is expected to significantly augment market growth

• North America dominated the allergy diagnostics & therapeutics market in 2022, due to an increase in understanding of the high potential associated with allergy drugs. This has driven U.S.-based firms to make considerable investments in the development of these drugs

• Asia Pacific is expected to witness considerable growth in the future owing to the rising incidences of asthma, chronic cough, and food allergies, among others, in the region



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.5.1. Commodity Flow Analysis
1.5.1.1. Approach 1: Commodity flow approach
1.5.1.2. Approach 2: Country-wise market estimation using bottom-up approach
1.6. Data Validation & Publishing
1.7. Global Market: CAGR Calculation
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segmental Snapshot
2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. Allergy Diagnostics & Therapeutics Market - Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising incidence of allergies
3.2.1.2. Advancements in technology and launch of new products
3.2.1.3. High adoption of immunotherapy drugs
3.2.2. Market Restraint Analysis
3.2.2.1. Low adoption and penetration in developing countries due to the high cost of technology
3.2.2.2. Lack of allergen standardization
3.3. Business Environmental Tools Analysis: Allergy Diagnostics & Therapeutics Market
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.4. Pipeline Analysis
Chapter 4. Allergy Diagnostics & Therapeutics Market: Type Estimates & Trend Analysis
4.1. Allergy Diagnostics & Therapeutics Market, By Type: Key Takeaways
4.2. Allergy Diagnostics & Therapeutics Market: Type Movement & Market Share Analysis, 2023 & 2030
4.3. Diagnostics
4.3.1. Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.2. Instruments
4.3.2.1. Global Instruments Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.3. Consumables
4.3.3.1. Global Consumables Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.4. Services
4.3.4.1. Global Services Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4. Therapeutics
4.4.1. Global Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2. Antihistamines
4.4.2.1. Global Antihistamines Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3. Decongestants
4.4.3.1. Global Decongestants Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.4. Corticosteroids
4.4.4.1. Global Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.5. Mast Cell Stabilizers
4.4.5.1. Global Mast Cell Stabilizers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.6. Leukotriene Inhibitors
4.4.6.1. Global Leukotriene Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.7. Nasal Anti-cholinergic
4.4.7.1. Global Nasal Anti-cholinergic Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.8. Immuno-modulators
4.4.8.1. Global Immuno-modulators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.9. Epinephrine
4.4.9.1. Global Epinephrine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.10. Immunotherapy
4.4.10.1. Global Immunotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Allergy Diagnostics & Therapeutics Market: Allergen Type Estimates & Trend Analysis
5.1. Allergy Diagnostics & Therapeutics Market, By Allergen type: Key Takeaways
5.2. Allergy Diagnostics & Therapeutics Market: Allergen type Movement & Market Share Analysis, 2023 & 2030
5.3. Food
5.3.1. Global Food Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.2. Dairy Products
5.3.2.1. Global Dairy Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.3. Poultry Product
5.3.3.1. Global Poultry Products Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.4. Tree Nuts
5.3.4.1. Global Tree Nuts Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.5. Peanuts
5.3.5.1. Global Peanut Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.6. Shellfish
5.3.6.1. Global Shellfish Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.7. Wheat
5.3.7.1. Global Wheat Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.8. Soy
5.3.8.1. Global Soy Allergy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3.9. Other Food Allergens
5.3.9.1. Global Food Allergens Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4. Inhaled
5.4.1. Global Inhaled Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5. Drug
5.5.1. Global Drug Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6. Others allergen types
5.6.1. Global Other allergen types Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Allergy Diagnostics Market: Test Type Estimates & Trend Analysis
6.1. Allergy Diagnostics Market, By Test Type: Key Takeaways
6.2. Allergy Diagnostics Market: Test Type Movement & Market Share Analysis, 2023 & 2030
6.3. In Vivo tests
6.3.1. Global In Vivo tests Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2. Skin Prick Test
6.3.2.1. Global Skin Prick Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3. Intradermal Test
6.3.3.1. Global Intradermal Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.4. Patch Test
6.3.4.1. Global Patch Test Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4. In Vitro tests
6.4.1. Global In Vitro tests Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Allergy Diagnostics & Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Allergy Diagnostics & Therapeutics Market: Regional Movement Analysis, 2023 & 2030
7.2. North America
7.2.1. North America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Prevalence Insights
7.2.2.4. Regulatory Framework
7.2.2.5. Reimbursement Structure
7.2.2.6. U.S. Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Prevalence Insights
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Structure
7.2.3.6. Canada Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Prevalence Insights
7.3.2.4. Regulatory Framework
7.3.2.5. Reimbursement Structure
7.3.2.6. UK Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Prevalence Insights
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Structure
7.3.3.6. Germany Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Prevalence Insights
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Structure
7.3.4.6. France Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Prevalence Insights
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Structure
7.3.5.6. Italy Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Prevalence Insights
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Structure
7.3.6.6. Spain Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Prevalence Insights
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Structure
7.3.7.6. Denmark Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Prevalence Insights
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Structure
7.3.8.6. Sweden Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Prevalence Insights
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Structure
7.3.9.6. Norway Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Prevalence Insights
7.4.2.4. Regulatory Framework
7.4.2.5. Reimbursement Structure
7.4.2.6. Japan Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Prevalence Insights
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Structure
7.4.3.6. China Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Prevalence Insights
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Structure
7.4.4.6. India Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Prevalence Insights
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Structure
7.4.5.6. Australia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Prevalence Insights
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Structure
7.4.6.6. Thailand Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Prevalence Insights
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Structure
7.4.7.6. South Korea Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Prevalence Insights
7.5.2.4. Regulatory Framework
7.5.2.5. Reimbursement Structure
7.5.2.6. Brazil Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Prevalence Insights
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Structure
7.5.3.6. Mexico Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Prevalence Insights
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Structure
7.5.4.6. Argentina Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East & Africa
7.6.1. Middle East & Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Prevalence Insights
7.6.2.4. Regulatory Framework
7.6.2.5. Reimbursement Structure
7.6.2.6. South Africa Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Prevalence Insights
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Structure
7.6.3.6. Saudi Arabia Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Prevalence Insights
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Structure
7.6.4.6. UAE Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Prevalence Insights
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Structure
7.6.5.6. Kuwait Allergy Diagnostics & Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Company Market Share Analysis, 2023
8.3. Strategy Mapping
8.4. Company Profiles/Listing
8.4.1. R-Biopharm AG
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. EUROIMMUN Medizinische Labordiagnostika AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. DASIT Group SPA
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. AESKU.GROUP GmbH
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. bioMérieux
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Danaher
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Thermo Fisher Scientific, Inc
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Stallergenes Greer
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Minaris Medical America, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Siemens Healthcare GmbH
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Omega Diagnostics Group PLC
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. HYCOR Biomedical
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Lincoln Diagnostics, Inc.
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
8.4.14. Alcon
8.4.14.1. Overview
8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.14.3. Product Benchmarking
8.4.14.4. Strategic Initiatives
8.4.15. HOB Biotech Group Corp., Ltd.
8.4.15.1. Overview
8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.15.3. Product Benchmarking
8.4.15.4. Strategic Initiatives
8.4.16. AbbVie Inc.
8.4.16.1. Overview
8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.16.3. Product Benchmarking
8.4.16.4. Strategic Initiatives
8.4.17. Allergy Therapeutics
8.4.17.1. Overview
8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.17.3. Product Benchmarking
8.4.17.4. Strategic Initiatives
8.4.18. Sanofi
8.4.18.1. Overview
8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.18.3. Product Benchmarking
8.4.18.4. Strategic Initiatives
8.4.19. Pfizer Inc.
8.4.19.1. Overview
8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.19.3. Product Benchmarking
8.4.19.4. Strategic Initiatives
8.4.20. Teva Pharmaceutical Industries Ltd.
8.4.20.1. Overview
8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.20.3. Product Benchmarking
8.4.20.4. Strategic Initiatives
8.4.21. Sun Pharmaceutical Industries Ltd.
8.4.21.1. Overview
8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.21.3. Product Benchmarking
8.4.21.4. Strategic Initiatives
8.4.22. GSK plc
8.4.22.1. Overview
8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.22.3. Product Benchmarking
8.4.22.4. Strategic Initiatives
8.4.23. F. Hoffmann-La Roche Ltd.
8.4.23.1. Overview
8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.23.3. Product Benchmarking
8.4.23.4. Strategic Initiatives
8.4.24. Merck & Co., Inc.
8.4.24.1. Overview
8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.24.3. Product Benchmarking
8.4.24.4. Strategic Initiatives
8.4.25. Astellas Pharma Inc.
8.4.25.1. Overview
8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.25.3. Product Benchmarking
8.4.25.4. Strategic Initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(diagnostics)の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/09 10:26

149.25 円

164.26 円

198.27 円

ページTOPに戻る